CIPRO I.V. - LIQ 10MG/ML LIQUID

国家: 加拿大

语言: 英文

来源: Health Canada

现在购买

下载 产品特点 (SPC)
05-06-2008

有效成分:

CIPROFLOXACIN (CIPROFLOXACIN LACTATE)

可用日期:

BAYER INC

ATC代码:

J01MA02

INN(国际名称):

CIPROFLOXACIN

剂量:

10MG

药物剂型:

LIQUID

组成:

CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 10MG

给药途径:

INTRAVENOUS

每包单位数:

40 ML

处方类型:

Prescription

治疗领域:

QUINOLONES

產品總結:

Active ingredient group (AIG) number: 0123207003; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2005-07-27

产品特点

                                © 2008, Bayer Inc.
® CIPRO is a registered trademard, used under license by Bayer Inc.
PRODUCT MONOGRAPH
CIPRO
®
(CIPROFLOXACIN HYDROCHLORIDE TABLETS)
250 MG, 500 MG, 750 MG
U.S.P.
CIPRO
® I.V.
(CIPROFLOXACIN INJECTION)
10 MG/ML IN WATER FOR INJECTION
BAYER STANDARD
CIPRO
® I.V. MINIBAGS
(CIPROFLOXACIN INJECTION)
2 MG/ML IN 5% DEXTROSE
BAYER STANDARD
CIPRO
® ORAL SUSPENSION
(CIPROFLOXACIN ORAL SUSPENSION)
10G/100 ML
BAYER STANDARD
ANTIBACTERIAL AGENT
BAYER INC.
DATE OF REVISION:
77 BELFIELD ROAD
JUNE 5, 2008
TORONTO, ONTARIO
M9W 1G6
CANADA
WWW.BAYER.CA
CONTROL NUMBER:
120682
2
PRODUCT MONOGRAPH
CIPRO
®
(Ciprofloxacin Hydrochloride Tablets)
250 mg, 500 mg, 750 mg
U.S.P.
CIPRO
®
I.V.
(Ciprofloxacin Injection)
10 mg/mL in Water for Injection
Bayer Standard
CIPRO
®
I.V. MINIBAGS
(Ciprofloxacin Injection)
2 mg/mL in 5% Dextrose
Bayer Standard
CIPRO
®
ORAL SUSPENSION
(Ciprofloxacin Oral Suspension)
10 g/100 mL
Bayer Standard
THERAPEUTIC CLASSIFICATION
Antibacterial Agent
3
ACTION AND CLINICAL PHARMACOLOGY
ACTION
Ciprofloxacin, a synthetic fluoroquinolone, has
_in vitro _
activity against a wide range of gram-
negative and gram-positive microorganisms. Its bactericidal action is
achieved through inhibition
of topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II
topoisomerases), which are
required for bacterial DNA replication, transcription, repair, and
recombination.
Ciprofloxacin retained some of its bactericidal activity after
inhibition of RNA and protein synthesis
by rifampin and chloramphenicol, respectively. These observations
suggest ciprofloxacin may
possess two bactericidal mechanisms, one mechanism resulting from the
inhibition of DNA gyrase
and a second mechanism which may be independent of RNA and protein
synthesis.
The mechanism of action of fluoroquinolones, including ciprofloxacin,
is different from that of
penicillins,
cephalosporins,
aminoglycosides,
macrolides,
and
tetracyclines.
Therefore,
microorganisms resistant to these classes of drugs may be susceptible
to ciprofloxacin. Co
                                
                                阅读完整的文件
                                
                            

其他语言的文件

产品特点 产品特点 法文 05-06-2008

搜索与此产品相关的警报